Mechanisms of hormonal therapy related thrombosis

Thrombosis Research

Volumn 131, Issue SUPPL.1, 2013, Pages

  Sandset, Per Morten ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Activated protein C resistance; Coagulation factors; Coagulation inhibitors; Hormone therapy; Oral contraceptives

Indexed keywords

ACTIVATED PROTEIN C; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LYNESTRENOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MESTRANOL; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACNE; ACTIVATED PROTEIN C RESISTANCE; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FIBRINOLYSIS; HEMOSTASIS; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; NONHUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; THROMBOPHILIA; TRANSDERMAL PATCH; VAGINA RING; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGENS; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE REPLACEMENT THERAPY; HORMONES; HUMANS; POSTMENOPAUSE; PROGESTINS; PROTEIN C; SEX HORMONE-BINDING GLOBULIN; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOSIS;

EID: 84875158660     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(13)70009-4     Document Type: Article

References (47)

1. FR Rosendaal, FM Helmerhorst, JP Vandenbroucke Female hormones and thrombosis Arterioscler Thromb Vasc Biol 22 2002 201 210
2. A van Hylckama Vlieg, S Middeldorp Hormone therapies and venous thromboembolism: where are we now? J Thromb Haemost 9 2011 257 266
3. PM Sandset, E Hoibraaten, AL Eilertsen, A Dahm Mechanisms of thrombosis related to hormone therapy Thromb Res 123 Suppl 2 2009 S70 S73
4. SN Tchaikovski, J Rosing Mechanisms of estrogen-induced venous thromboembolism Thromb Res 126 2010 5 11
5. WM Jordan, JK Anand Pulmonary embolism The Lancet 278 1961 1146 1147
6. ET Tyler Oral contraception and venous thrombosis JAMA 185 1963 131 132
7. O Lidegaard, LH Nielsen, CW Skovlund, FE Skjeldestad, E Lokkegaard Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 BMJ 343 2011 d6423
8. O Lidegaard, E Lokkegaard, AL Svendsen, C Agger Hormonal contraception and risk of venous thromboembolism: national follow-up study BMJ 339 2009 b2890
9. A van Hylckama Vlieg, FM Helmerhorst, JP Vandenbroucke, CJ Doggen, FR Rosendaal The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study BMJ 339 2009 b2921
10. PM Sandset, E Høibraaten, AL Eilertsen Hormone replacement therapy and coagulation. The Menopause 2006 Elsevier Edinburgh
11. HD Nelson, M Walker, B Zakher, J Mitchell Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations Ann Intern Med 157 2012 104 113
12. E Hoibraaten, E Qvigstad, H Arnesen, S Larsen, E Wickstrom, PM Sandset Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET) Thromb Haemost 84 2000 961 967
13. S Middeldorp, JC Meijers, AE van den Ende, A van Enk, BN Bouma, G Tans, J Rosing, MH Prins, HR Buller Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study Thromb Haemost 84 2000 4 8
14. G Tans, J Curvers, S Middeldorp, MC Thomassen, JC Meijers, MH Prins, BN Bouma, HR Buller, J Rosing A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways Thromb Haemost 84 2000 15 21
15. JM Kemmeren, A Algra, JC Meijers, G Tans, BN Bouma, J Curvers, J Rosing, DE Grobbee Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial Blood 103 2004 927 933
16. RR Koenen, M Christella, LG Thomassen, G Tans, J Rosing, TM Hackeng Effect of oral contraceptives on the anticoagulant activity of protein S in plasma Thromb Haemost 93 2005 853 859
17. GM Harris, CL Stendt, BJ Vollenhoven, TE Gan, PG Tipping Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives Am J Hematol 60 1999 175 180
18. A Dahm, HV Van, B Bendz, F Rosendaal, RM Bertina, PM Sandset Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis Blood 101 2003 4387 4392
19. HA van Vliet, RM Bertina, AE Dahm, FR ROSENDAAL, J Rosing, PM Sandset, FM Helmerhorst Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor J Thromb Haemost 6 2008 346 351
20. M Raps, FM Helmerhorst, K Fleischer, AEA Dahm, FR ROSENDAAL, P Reitsma, PM Sandset, HAAM van Vliet The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI Thromb Haemost 2013
21. JC Meijers, S Middeldorp, W Tekelenburg, AE van den Ende, G Tans, MH Prins, J Rosing, HR Buller, BN Bouma Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives Thromb Haemost 84 2000 9 14
22. AL Eilertsen, L Sandvik, MC Mowinckel, TO Andersen, E Qvigstad, PM Sandset Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis Thromb Res 120 2007 371 379
23. E Hoibraaten, E Qvigstad, TO Andersen, MC Mowinckel, PM Sandset The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind, clinical trial Thromb Haemost 85 2001 775 781
24. AL Eilertsen, E Qvigstad, TO Andersen, L Sandvik, PM Sandset Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation Maturitas 55 2006 278 287
25. AL Eilertsen, E Hoibraaten, I Os, TO Andersen, L Sandvik, PM Sandset The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis Maturitas 52 2005 111 118
26. AL Eilertsen, L Sandvik, B Steinsvik, PM Sandset Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers J Thromb Haemost 6 2008 928 934
27. O Olivieri, S Friso, F Manzato, A Guella, F Bernardi, B Lunghi, D Girelli, M Azzini, G Brocco, C Russo Resistance to activated protein C in healthy women taking oral contraceptives Br J Haematol 91 1995 465 470
28. J Rosing, G Tans, GA Nicolaes, MC Thomassen, R Van Oerle, PM van der Ploeg, P Heijnen, K Hamulyak, HC Hemker Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives Br J Haematol 97 1997 233 238
29. J Rosing, S Middeldorp, J Curvers, M Christella, LG Thomassen, GA Nicolaes, JC Meijers, BN Bouma, HR Buller, MH Prins, G Tans Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study Lancet 354 1999 2036 2040
30. AL Eilertsen, S Liestol, MC Mowinckel, HC Hemker, PM Sandset Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system Thromb Haemost 97 2007 938 943
31. MC de Visser, HV Van, G Tans, J Rosing, AE Dahm, PM Sandset, FR Rosendaal, RM Bertina Determinants of the APTT- and ETP-based sensitivity tests J Thromb Haemost 3 2005 1488 1494
32. MC de Visser, FR Rosendaal, RM Bertina A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis Blood 93 1999 1271 1276
33. J Curvers, MC Thomassen, J Rimmer, K Hamulyak, J VAN DER MEER, G Tans, FE PRESTON, J Rosing Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test Thromb Haemost 88 2002 5 11
34. A Bergrem, AE Dahm, AF Jacobsen, MC Mowinckel, L Sandvik, PM Sandset Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism Br J Haematol 154 2011 241 247
35. E Hoibraaten, MC Mowinckel, RH de, RM Bertina, PM Sandset Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial Br J Haematol 115 2001 415 420
36. SN Tchaikovski, BJ van Vlijmen, AC Cleuren, MC Thomassen, V Tchaikovski, G Tans, J Rosing Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice J Thromb Haemost 7 2009 312 318
37. JE Rossouw, KC Johnson, M Pettinger, M Cushman, PM Sandset, L Kuller, F Rosendaal, J Rosing, S Wasserthal-Smoller, LW Martin, JE Manson, K Laksh-minarayan, JG Merino, J Lynch Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy Stroke 43 2012 952 957
38. U Goebelsmann, CA Mashchak, DR Mishell Jr Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol Am J Obstet Gynecol 151 1985 868 877
39. H Kuhl Comparative pharmacology of newer progestogens Drugs 51 1996 188 215
40. V Odlind, I Milsom, I Persson, A Victor Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 81 2002 482 490
41. AL Eilertsen, E Høibraaten, CM Lofthus, MC Mowinckel, PM Sandset Differential impact of conventional and low dose oral hormone therapy (HT) on sex hormone binding globulin (SHBG) J Thromb Haemost 7 Suppl 2 2009 79 (Abstract AS-TH-004).
42. HA van Vliet, SN Tchaikovski, FR Rosendaaal, J Rosing, FM Helmerhorst The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC) Thromb Haemost 101 2009 691 695
43. JP Vandenbroucke, T Koster, E Briet, PH Reitsma, RM Bertina, FR ROSENDAAL Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation Lancet 344 1994 1453 1457
44. DM Herrington, E Vittinghoff, TD Howard, DA Major, J Owen, DM Reboussin, D Bowden, V Bittner, JA Simon, D Grady, SB Hulley Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease Arterioscler Thromb Vasc Biol 22 2002 1012 1017
45. PG Lindqvist, J Rosing, A Malmquist, A Hillarp Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system J Thromb Haemost 1 2003 601 602
46. S Jick, JA Kaye, L Li, H Jick Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol Contraception 76 2007 4 7
47. DD Dore, H Norman, J Loughlin, JD Seeger Extended case-control study results on thrombo-embolic outcomes among transdermal contraceptive users Contraception 81 2010 408 413